In this podcast, Dr. Christopher Flowers discusses new research from the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition, including new treatments for non-Hodgkin lymphoma and models for predicting early disease progression.
Read research from the December 2022 session of the ASCO Plenary Series, which explores combining immunotherapy for advanced non-small cell lung cancer with high PD-L1.
A study from China published in the Journal of Clinical Oncology has shown that CAR T-cell therapy that targets CD19 and CD22 is effective at treating recurrent or refractory acute lymphoblastic leukemia in children.
Drs. David Ilson, Sumanta (Monty) Pal, and Tian Zhang discuss new research presented at the 2022 ESMO Congress, including studies about treating liver, colorectal, stomach, kidney, bladder, and prostate cancers.
In this podcast, 3 Cancer.Net Associate Editors discuss new research presented at the 2022 ASCO Annual Meeting in non-small cell lung cancer, non-Hodgkin lymphoma, Ewing sarcoma, and neuroblastoma.
In this podcast, experts discuss what people with early-stage lung cancer should know about molecular testing, including what it is, how it may be used in guiding treatment decisions, and several recent studies about its role in treatment planning.
Read research from the April 2022 session of the ASCO Plenary Series, which highlights a clinical trial that studied a medication called tislelizumab combined with chemotherapy to treat recurrent or metastatic nasopharyngeal cancer.
Read research from the March 2022 session of the ASCO Plenary Series, which highlights an immunotherapy combination to treat advanced melanoma and adding immunotherapy to chemotherapy to treat advanced non-small cell lung cancer.
In this podcast, Dr. Christopher Flowers discusses research from the 2021 American Society of Hematology (ASH) Annual Meeting and Exposition, including studies evaluating new treatments for diffuse large B-cell lymphoma and an overview of a session on improving equity in cancer clinical trials.
Research from ASCO’s 2022 Gastrointestinal Cancers Symposium will feature 2 abstracts that looked at using immunotherapy to treat advanced liver cancer and biliary tract cancer.
